Lunaphore raises an additional CHF 2m, bringing total Series C to CHF 25m
Our portfolio company, LUNAPHORE, raised an additional CHF 2m in Series C2 financing round, bringing total Series C to CHF 25m. The Swiss life-sciences company developing innovative next-generation equipment for cancer research and tissue diagnostics announced a first closing on February 6, 2020 with CHF 23m.
The proceeds of the overall Series C will be dedicated to market and product expansion, including a US market entry, the ramp up of activities in Europe and the development of the next generation of instruments.
We congratulate the whole LUNAPHORE team for this closing.